LINC01619: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01619

NCBI ID: G256021

LINC01619

Other Name(s): Long intergenic non-protein coding RNA 1619, transcript variant 3 | Long intergenic non-protein coding RNA 1619, transcript variant 1 | Long intergenic non-protein coding RNA 1619, transcript variant 5 | HCG1809058, isoform CRA_c | Uncharacterized protein | Uncharacterized protein encoded by LINC01619 | Long intergenic non-protein coding RNA 1619, transcript variant 2 | uncharacterized LOC256021 | uncharacterized protein LOC256021 | C12orf79 | long intergenic non-protein coding RNA 1619 | Long intergenic non-protein coding RNA 1619, transcript variant 4 | LOC256021 variant 1 | Uncharacterized protein LOC256021 (isoform 1) | CL079_HUMAN | Uncharacterized LOC256021, transcript variant 1

LINC01619: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01619 is a long intergenic non-protein-coding RNA (lncRNA) with a transcript variant number of 3. It is a non-coding RNA molecule that has been identified in various organisms, including humans. LINC01619 is known to play a crucial role in cellular processes, and its expression levels have been associated with various diseases, including cancer.

Drug Targeting

LINC01619 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. The non-coding RNA is known to interact with several protein molecules, including the protein encoded by the gene ENSL1 (Ensign-Nunally syndrome-like 1).

The interaction between LINC01619 and ENSL1 has been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and translation. LINC01619 has been shown to physically interact with ENSL1 through its binding to the protein's RNA-binding domain.

Biomarker

LINC01619 has also been identified as a potential biomarker for various diseases, including cancer. The non-coding RNA has been shown to be highly expressed in various cancer tissues, including breast cancer, lung cancer, and colon cancer.

The expression of LINC01619 has also been shown to be associated with the development of cancer-associated biomarkers, such as the expression of the protein PD-L1. PD-L1 is a transmembrane protein that has been shown to promote the immune response and has been implicated in various diseases, including cancer.

Expression of LINC01619 has also been shown to be associated with the development of other biomarkers, such as the expression of the protein GUS2, which is known to be involved in the development of various diseases, including cancer.

Conclusion

In conclusion, LINC01619 is a long intergenic non-protein-coding RNA that has been identified in various organisms, including humans. Its expression levels have been associated with various diseases, including cancer. The non-coding RNA has also been shown to interact with several protein molecules, including the protein encoded by the gene ENSL1.

Further research is needed to fully understand the role of LINC01619 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1619

The "LINC01619 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01619 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets